OTCMKTS:PHGUF Pharming Group Q1 2026 Earnings Report $1.11 0.00 (0.00%) As of 10/1/2026 ProfileEarnings History Pharming Group EPS ResultsActual EPS-$0.01Consensus EPS $0.00Beat/MissMissed by -$0.01One Year Ago EPSN/APharming Group Revenue ResultsActual Revenue$72.45 millionExpected Revenue$92.06 millionBeat/MissMissed by -$19.61 millionYoY Revenue GrowthN/APharming Group Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsPharming Group's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Pharming Group Earnings HeadlinesPharming Group: Viable Contrarian Buy If Ruconest StabilizesSeptember 30 at 8:31 AM | seekingalpha.comPharming Wins FDA Priority Review for Lower-Dose Joenja in Younger APDS PatientsSeptember 25, 2026 | tipranks.comHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.October 2 at 1:00 AM | Chaikin Analytics (Ad)Pharming posts positive Phase II data for leniolisib in rare immune disordersSeptember 22, 2026 | tipranks.comPharming wins FDA nod to extend Joenja use to younger APDS childrenSeptember 11, 2026 | tipranks.comPharming Group Steps Up Investor Outreach With September Conference LineupSeptember 9, 2026 | tipranks.comSee More Pharming Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharming Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharming Group and other key companies, straight to your email. Email Address About Pharming GroupPharming Group (OTCMKTS:PHGUF) N.V. is a Netherlands-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company’s activities include research and development, regulatory approval, manufacturing, and global commercialization of medicines for patients with limited treatment options. Pharming’s principal product is Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare and potentially life-threatening genetic disorder. Ruconest is produced using Pharming’s proprietary transgenic production technology and is approved in several markets, including the United States and European Union. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome, or APDS. Joenja was approved in the United States in 2023 and is intended for patients aged 12 and older with this rare primary immunodeficiency. Pharming continues to evaluate opportunities to expand access to its products and advance additional therapies for rare diseases. Pharming was founded in 1988 and is headquartered in Leiden, the Netherlands. Its medicines are supplied to patients through commercial and distribution activities in multiple international markets. Sijmen de Vries has served as the company’s chief executive officer and executive director for much of its commercial development.View Pharming Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
